Residual Prostate Cancer After Radiotherapy: A Study of Radical Cystoprostatectomy Specimens

Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Urology (Impact Factor: 2.19). 03/2008; 72(3):654-8. DOI: 10.1016/j.urology.2007.11.020
Source: PubMed


The incidence of histologic prostate cancer (CaP) after definitive radiation therapy (RT) for localized disease is rarely quantitated. We investigated the relationship between prostate-specific antigen (PSA) and histologically residual CaP after definitive RT in patients undergoing radical cystoprostatectomy (RCP) for unrelated indications.
We reviewed our prostate cancer database to identify patients undergoing RCP who previously received definitive RT for localized CaP. Pre-radiation variables examined include PSA, Gleason score, radiation modality, and dose. Post-radiation variables reviewed include PSA, time to RCP, the presence of histologically proven prostate cancer, and Gleason score.
We identified 21 patients who underwent RCP at a median of 60 months after RT for localized CaP. Pre-radiation Gleason scores were low (6 or less) to intermediate risk (3+4) in 82% (14 of 17), intermediate (4+3) to high (8 or greater) in 18% (3 of 17), and unavailable in 4 patients. Median pre-radiation PSA was 9 ng/mL. Median PSA before RCP in all patients was 0.8 ng/mL. A total of 52% (11 of 21) of patients demonstrated active CaP in the RCP specimen. Although 89% (16 of 18) of patients met the Phoenix definition of biochemical freedom from disease, 50% (8 of 16) of these patients had histologically residual CaP at the time of RCP. Median PSA was not significantly different between patients with and without active CaP.
Histologic evidence of CaP was noted in 50% of patients demonstrating biochemical freedom from disease at the time of RCP. Although the biological significance of active CaP in this select population is uncertain, our findings demonstrate the limitations of PSA in monitoring CaP disease activity after definitive RT.

Download full-text


Available from: Richard E Greenberg, Jul 13, 2015
6 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Salvage radical prostatectomy (SRP) for radiorecurrent prostate cancer (PCa) is a second local treatment with curative intent in patients with true organ-confined recurrent PCa. We evaluated preoperative prognostic risk factors to predict organ-confined, locally recurrent PCa after primary radiotherapy (RT). Fifty-five men with biopsy-proven, locally recurrent PCa underwent SRP and extended pelvic lymph node dissection (ePLND) after external-beam radiotherapy (EBRT) or low- or high-dose brachytherapy. Prostate-specific antigen (PSA), clinical stage, biopsy Gleason score prior to RT and SRP, PSA nadir, time to recurrence, PSA doubling time (PSA DT), PSA prior to surgery, and pathohistology of the SRP specimen were analysed to predict organ-confined recurrent disease. Uni- and multivariate statistical analysis was performed. Forty (72.7%) and 15 (27.3%) patients demonstrated organ-confined and locally advanced PCa, respectively. Eleven patients (20%) and seven patients (12.7%) had lymph node metastases and positive surgical margins (PSM), respectively. On multivariate analysis, biopsy Gleason score prior to SRP (p=0.02), <50% positive biopsy cores (p=0.001), PSA DT >12 mo (p=0.001), and low-dose brachytherapy (p=0.001) were significant predictors of organ-confined PCa with negative surgical margins (NSM). Limitations of the study are its retrospective nature and the relatively low number of patients. SRP is a surgically challenging but effective secondary local treatment of radiorecurrent PCa with curative intent. The identified predictive parameters will help to select patients most suitable for SRP with long-term cure and good functional outcome.
    European Urology 03/2009; 57(3):437-43. DOI:10.1016/j.eururo.2009.02.041 · 13.94 Impact Factor
  • Actas urologicas españolas 01/2010; 34(1):6-9. DOI:10.1016/S2173-5786(10)70003-2 · 1.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Over half of men that receive treatment for prostate cancer (PCa) will choose radiotherapy (RT). After RT, recurrence is determined by a rise in PSA and not usually by pathologic confirmation. We describe the prevalence of persistent gradable PCa in men treated with radiotherapy for PCa at radical cystoprostatectomy (RC) for bladder cancer. Seventy-eight patients underwent RT (brachytherapy, external-beam radiation or both) prior to development of bladder cancer requiring RC at our institution. All tissues were evaluated by a specialized GU pathologist. The median time from radiotherapy to RC was 77 months. Gradable PCa was identified in 45% of patients, with 69% of tumors Gleason score 7 or greater and 17% with = pT3 and 5% with positive lymph nodes. Men treated more recently were less likely to have gradable PCa (100% prior to 1980 and, 49% between 1980-2000, and 10% 2000 to current, p=0.002) as well as men receiving EBRT alone (58%) compared to brachytherapy (27%) and combined brachytherapy/EBRT (14%) (p=0.005). After RT, 45% of men had persistent PCa (37% of men who were NED) with a decrease in PCa rates associated with later years of treatment and the usage of combined brachytherapy/EBRT regimens. Similar to men undergoing RC for muscle-invasive bladder cancer, meticulous attention should be paid during prostate removal in men treated with RT as many may have persistent PCa. In addition, markers other than PSA should be studied in men treated with RT to better identify men with BCR.
    The Journal of urology 12/2013; 191(6). DOI:10.1016/j.juro.2013.12.037 · 4.47 Impact Factor
Show more